AR089666A1 - Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico - Google Patents
Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceuticoInfo
- Publication number
- AR089666A1 AR089666A1 ARP130100039A ARP130100039A AR089666A1 AR 089666 A1 AR089666 A1 AR 089666A1 AR P130100039 A ARP130100039 A AR P130100039A AR P130100039 A ARP130100039 A AR P130100039A AR 089666 A1 AR089666 A1 AR 089666A1
- Authority
- AR
- Argentina
- Prior art keywords
- acceptable salts
- pharmaceutical
- viewpoint
- montelukast
- oral administration
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 title abstract 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title abstract 3
- 229960001508 levocetirizine Drugs 0.000 title abstract 3
- 229960005127 montelukast Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000007524 organic acids Chemical class 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a una formulación farmacéutica para administración oral para prevenir o tratar la rinitis alérgica o el asma, que comprende: (a) una primera parte de partículas que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmacéutico y un ácido orgánico; y (b) una segunda parte de partículas que comprende montelukast o una de sus sales aceptables desde el punto de vista farmacéutico. La formulación farmacéutica de acuerdo con la presente comprende un ácido orgánico como agente estabilizador, que puede inhibir en forma efectiva la producción de levocetirizina y sustancias relacionadas con montelukast, y de este modo, muestran buena estabilidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120001954A KR101418404B1 (ko) | 2012-01-06 | 2012-01-06 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089666A1 true AR089666A1 (es) | 2014-09-10 |
Family
ID=48745292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100039A AR089666A1 (es) | 2012-01-06 | 2013-01-04 | Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico |
Country Status (21)
Country | Link |
---|---|
US (1) | US9486528B2 (es) |
EP (1) | EP2800558B1 (es) |
JP (1) | JP6163165B2 (es) |
KR (1) | KR101418404B1 (es) |
CN (1) | CN104039314B (es) |
AR (1) | AR089666A1 (es) |
BR (1) | BR112014016472B1 (es) |
ES (1) | ES2671428T3 (es) |
HK (1) | HK1200337A1 (es) |
JO (1) | JO3388B1 (es) |
MX (1) | MX354073B (es) |
PH (1) | PH12014501545B1 (es) |
PL (1) | PL2800558T3 (es) |
PT (1) | PT2800558T (es) |
RU (1) | RU2614382C2 (es) |
SG (1) | SG11201403811VA (es) |
SI (1) | SI2800558T1 (es) |
TR (1) | TR201807978T4 (es) |
TW (1) | TWI565482B (es) |
WO (1) | WO2013103262A1 (es) |
ZA (1) | ZA201405756B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106456535B (zh) * | 2014-04-25 | 2020-07-03 | R.P.谢勒技术有限公司 | 稳定的孟鲁司特溶液 |
KR101669556B1 (ko) * | 2014-07-02 | 2016-10-28 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제 |
JP6575031B2 (ja) * | 2014-07-28 | 2019-09-18 | 日本ケミファ株式会社 | モンテルカストナトリウム製剤 |
RU2580303C1 (ru) * | 2015-02-18 | 2016-04-10 | Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" | Состав таблетированной формы лекарственного средства с действующим веществом пророксан |
EP3222279B1 (en) | 2016-03-21 | 2021-11-17 | Invest Bielany Spolka z ograniczona odpowiedzialnoscia | Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production |
KR102481517B1 (ko) * | 2021-08-30 | 2022-12-27 | 주식회사 클라시아 | 약제학적 제제 |
JP2024514989A (ja) * | 2021-10-21 | 2024-04-03 | ハン ファ ファーマ カンパニー、リミテッド | モンテルカストまたはその薬学的に許容可能な塩、及びレボセチリジンまたはその薬学的に許容可能な塩を含有する、安定性が改善されたフィルムコーティング錠剤 |
KR20240045586A (ko) | 2022-09-30 | 2024-04-08 | 주식회사 제뉴원사이언스 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1204580A (en) | 1968-10-05 | 1970-09-09 | Aspro Nicholas Ltd | Pharmaceutical dosage forms |
DK154078C (da) | 1981-02-06 | 1989-05-22 | Ucb Sa | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf |
US4800162A (en) | 1987-04-01 | 1989-01-24 | Sepracor, Inc. | Method for resolution of steroisomers in multiphase and extractive membrane reactors |
US5057427A (en) | 1988-04-07 | 1991-10-15 | Sepracor, Inc. | Method for resolution of stereoisomers |
GB8827391D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
GB8827390D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
DE4209824A1 (de) | 1991-09-06 | 1993-03-11 | Schaeffler Waelzlager Kg | Waelzlager fuer linearbewegungen |
GB9305282D0 (en) | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
BE1010094A3 (fr) | 1996-04-10 | 1997-12-02 | Ucb Sa | Nouveaux [2-(1-piperazinyl)ethoxy] methyle substitues. |
BE1010095A3 (fr) | 1996-04-10 | 1997-12-02 | Ucb Sa | Procede de preparation de l'acide 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl] ethoxy]-acetique et de ses sels. |
DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
CA2405233A1 (en) * | 2000-04-12 | 2001-10-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
KR100795419B1 (ko) * | 2006-01-03 | 2008-01-17 | (주)네오메딕스 | 암로디핀 및 아스피린을 함유하는 약학 제제 |
KR100910848B1 (ko) * | 2007-09-13 | 2009-08-06 | 재단법인서울대학교산학협력재단 | 알러지성 비염 치료약물을 유효성분으로 함유하는 비강분무용 마이크로스피어 및 이의 제조방법 |
WO2010107404A1 (en) * | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
KR20130009553A (ko) | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
KR101861307B1 (ko) * | 2011-10-13 | 2018-07-06 | 한미약품 주식회사 | 정제를 포함하는 경질 캡슐 복합 제형 |
-
2012
- 2012-01-06 KR KR1020120001954A patent/KR101418404B1/ko active IP Right Grant
-
2013
- 2013-01-03 JO JOP/2013/0004A patent/JO3388B1/ar active
- 2013-01-04 SI SI201331005T patent/SI2800558T1/en unknown
- 2013-01-04 PL PL13733789T patent/PL2800558T3/pl unknown
- 2013-01-04 MX MX2014008059A patent/MX354073B/es active IP Right Grant
- 2013-01-04 EP EP13733789.5A patent/EP2800558B1/en active Active
- 2013-01-04 US US14/370,258 patent/US9486528B2/en active Active
- 2013-01-04 TW TW102100251A patent/TWI565482B/zh not_active IP Right Cessation
- 2013-01-04 BR BR112014016472-0A patent/BR112014016472B1/pt active IP Right Grant
- 2013-01-04 PT PT137337895T patent/PT2800558T/pt unknown
- 2013-01-04 WO PCT/KR2013/000057 patent/WO2013103262A1/en active Application Filing
- 2013-01-04 ES ES13733789.5T patent/ES2671428T3/es active Active
- 2013-01-04 CN CN201380004854.0A patent/CN104039314B/zh active Active
- 2013-01-04 RU RU2014132428A patent/RU2614382C2/ru not_active IP Right Cessation
- 2013-01-04 SG SG11201403811VA patent/SG11201403811VA/en unknown
- 2013-01-04 TR TR2018/07978T patent/TR201807978T4/tr unknown
- 2013-01-04 JP JP2014551191A patent/JP6163165B2/ja not_active Expired - Fee Related
- 2013-01-04 AR ARP130100039A patent/AR089666A1/es not_active Application Discontinuation
-
2014
- 2014-07-03 PH PH12014501545A patent/PH12014501545B1/en unknown
- 2014-08-05 ZA ZA2014/05756A patent/ZA201405756B/en unknown
-
2015
- 2015-01-23 HK HK15100824.5A patent/HK1200337A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PH12014501545A1 (en) | 2014-10-08 |
ES2671428T3 (es) | 2018-06-06 |
TW201332590A (zh) | 2013-08-16 |
HK1200337A1 (en) | 2015-08-07 |
EP2800558A4 (en) | 2015-08-12 |
US9486528B2 (en) | 2016-11-08 |
MX2014008059A (es) | 2014-10-06 |
JO3388B1 (ar) | 2019-03-13 |
JP6163165B2 (ja) | 2017-07-12 |
MX354073B (es) | 2018-02-12 |
KR101418404B1 (ko) | 2014-07-10 |
CN104039314A (zh) | 2014-09-10 |
SG11201403811VA (en) | 2014-08-28 |
SI2800558T1 (en) | 2018-06-29 |
PH12014501545B1 (en) | 2014-10-08 |
KR20130081013A (ko) | 2013-07-16 |
RU2614382C2 (ru) | 2017-03-24 |
BR112014016472B1 (pt) | 2022-03-15 |
BR112014016472A2 (pt) | 2017-06-13 |
TWI565482B (zh) | 2017-01-11 |
JP2015503579A (ja) | 2015-02-02 |
PL2800558T3 (pl) | 2018-08-31 |
TR201807978T4 (tr) | 2018-06-21 |
CN104039314B (zh) | 2017-07-14 |
US20140356422A1 (en) | 2014-12-04 |
EP2800558B1 (en) | 2018-04-11 |
WO2013103262A1 (en) | 2013-07-11 |
RU2014132428A (ru) | 2016-02-27 |
BR112014016472A8 (pt) | 2017-07-04 |
ZA201405756B (en) | 2016-08-31 |
PT2800558T (pt) | 2018-06-05 |
EP2800558A1 (en) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089666A1 (es) | Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
MX2015010971A (es) | Derivado novedoso de pirazol. | |
NZ725008A (en) | Compounds for treating spinal muscular atrophy | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
NZ631100A (en) | Soft chewable pharmaceutical products | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
BR112018006922A2 (pt) | composições farmacêuticas estabilizantes de camptotecina | |
MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
IN2014DN06869A (es) | ||
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
NZ721780A (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
MX2016014946A (es) | Derivados de carboxamida. | |
UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
BR112016023991A2 (pt) | ativadores de herg policíclicos | |
BR112016015175A2 (pt) | Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido | |
BR112016029417A2 (pt) | desmopressina estabilizada | |
BR112017010841A2 (pt) | formulações de um inibidor da pi3k/mtor para administração intravenosa | |
PH12016502247A1 (en) | Carboxamide derivatives | |
BR112015022970A2 (pt) | composição farmacêutica de cloridrato de s-cetamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |